Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4510 results

Sort By:

Guiding Opioid Administration by Nociception Level Index (NOL) in Patients with Regional Anesthesia

Study ID: NCT06905340
Start Date: 2025-04
End Date: 2026-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

240

Intervention / Treatment

NOL (Nociception Level Index)

Control (Standard treatment)

Sponsor

University Hospital Hamburg-Eppendorf

Source: clinicaltrials.gov

Share:
Add to list

Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines

Study ID: NCT06676644
Start Date: 2025-11-05
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

200

Intervention / Treatment

adjuvanted

non-adjuvanted

Sponsor

National Taiwan University Hospital

Source: clinicaltrials.gov

Share:
Add to list

Michigan Split-belt Treadmill Training Program to Improve Long-Term Knee Biomechanics After ACL Reconstruction

Study ID: NCT06529692
Start Date: 2025-04
End Date: 2026-08
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

9

Intervention / Treatment

Placebo Split-Belt Training

Split-Belt Training

Sponsor

University of Michigan

Source: clinicaltrials.gov

Share:
Add to list

Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

Study ID: NCT06719440
Start Date: 2025-04
End Date: 2031-10
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

347

Intervention / Treatment

Radiotherapy

Sponsor

Saint-Luc university clinics- Catholic University of Louvain

Source: clinicaltrials.gov

Share:
Add to list

Enfortumab Vedotin Plus Pembrolizumab with Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Study ID: NCT06809140
Start Date: 2025-04
End Date: 2029-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

47

Intervention / Treatment

Emportumab Vedotin

Pembrolizumab

Sponsor

Matthew Galsky

Source: clinicaltrials.gov

Share:
Add to list

Prebiotic Effects of Mulberry Fruit in Children and Adolescents with Atopic Dermatitis

Study ID: NCT06636240
Start Date: 2025-04-01
End Date: 2026-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

Mulberry fruit juice

Fluticasone

Sponsor

Taipei Medical University Shuang ho hospital hospital hospital hospital

Source: clinicaltrials.gov

Share:
Add to list

Adapting the Fear of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility

Study ID: NCT06872840
Start Date: 2025-05-26
End Date: 2027-05-26
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

36

Intervention / Treatment

Parent Fear of Recurrence Therapy (Parent-FORT)

Sponsor

University of Ottawa

Source: clinicaltrials.gov

Share:
Add to list

Exploring the Influence of Trptophan on the Treatment of Pouchitis

Study ID: NCT06861140
Start Date: 2025-04-01
End Date: 2027-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Tryptophan 25mg/kg bodyweight

Placebo

Sponsor

University Hospital Hamburg-Eppendorf

Source: clinicaltrials.gov

Share:
Add to list

Genetic Analysis of Uncommon Disease Presentations in Non-US Populations

Study ID: NCT06595940
Start Date: 2025-04-04
End Date: 2034-08-21
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

400

Intervention / Treatment
Sponsor

National Human Genome Research Institute (NHGRI)

Source: clinicaltrials.gov

Share:
Add to list

A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury

Study ID: NCT06870240
Start Date: 2025-06-01
End Date: 2026-03-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Neurosteroid enantiomer

Sponsor

Oragenics, Inc.

Source: clinicaltrials.gov

Share:
Add to list